Physician profile
Amy Young
NPI 1891410395
$2,522.15
in general payments reported to CMS, 2019-2025
33 companies · $1,713 in 2025
The $1,713 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $395 · 2024: $414 · 2025: $1,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,427.15 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $290.31 | 2024-2025 | Erleada, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $231.29 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $229.37 | 2023-2025 | Enhertu, Calquence, Imfinzi |
| Incyte Corporation | $172.96 | 2023-2025 | Monjuvi, Pemazyre, Zynyz |
| Daiichi Sankyo INC. | $149.60 | 2023-2025 | Enhertu, Vanflyta |
| Astellas Pharma US INC | $147.00 | 2023-2025 | Xospata |
| Genentech, INC. | $103.73 | 2023 | Tecentriq |
| Eisai INC. | $98.21 | 2025 | |
| Genmab U.S., INC. | $91.84 | 2024-2025 | Tivdak |
| Tempus Ai, INC | $78.14 | 2025 | Xt Cdx |
| Pharmacosmos Therapeutics INC. | $73.26 | 2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $72.71 | 2023-2025 | |
| Pfizer INC. | $68.33 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $65.60 | 2024-2025 | Libtayo |
| Sobi, INC | $64.36 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $59.41 | 2024-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $55.85 | 2023-2025 | Orgovyx |
| Genentech USA, INC. | $53.40 | 2024-2025 | Polivy, Lunsumio, Columvi |
| Celgene Corporation | $50.74 | 2024-2025 | Reblozyl |
| Beone Medicines USA, INC. | $49.62 | 2025 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $49.54 | 2023-2024 | Myrisk |
| Caris Mpi, INC. | $46.36 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $26.68 | 2025 | Fruzaqla |
| Servier Pharmaceuticals LLC | $24.87 | 2024 | |
| Seagen INC. | $23.85 | 2023 | Adcetris |
| Glaxosmithkline, LLC. | $22.87 | 2024 | Jemperli, Zejula |
| Exelixis INC. | $22.44 | 2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $19.16 | 2025 | Keytruda |
| Recordati_rare_diseases_inc. | $17.16 | 2024 | Panhematin |
| Abbvie INC. | $17.00 | 2023 | |
| Gilead Sciences, INC. | $16.38 | 2023 | |
| Adaptive Biotechnologies Corporation | $15.73 | 2024 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.